Status:
COMPLETED
Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to correlate molecular genetic profile with response to chemotherapy in case of primary chemotherapy treatment for non-small cells lung carcinoma.
Detailed Description
Lung carcinoma will be the fifth death cause in the world in 2020. In Europe it causes more deaths than carcinoma of breast, colon and prostate combined so it is a public healthcare priority. Applying...
Eligibility Criteria
Inclusion
- Patient older than 18 suffering from Non-Small-Cell Lung Carcinoma
- Patient treated by chemotherapy with platinum salt
- Every stage TNM classification
- No previous chemotherapy
- One measurable lesion out of nervous central system at least
- Performance status from 0 to 2 on ECOG scale
- Life expectancy \> 12 weeks
Exclusion
- Previous or Concomitant carcinoma over 5 last years
- Concomitant radiotherapy
- Cardiac disease
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
556 Patients enrolled
Trial Details
Trial ID
NCT00222404
Start Date
July 1 2005
End Date
August 1 2010
Last Update
November 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Grenoble
Grenoble, France, 38000